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A rapid and sensitive method for quantitative determination of paclitaxel in rat plasma
was developed and validated by using ultra-performance liquid chromatography-tandem
mass spectrometry (UPLC-MS/MS). Docetaxel was used as an internal standard and
diethyl ether was the liquideliquid extraction agent. Multiple reaction monitoring (MRM)
mode via positive electrospray ionization (ESI) was applied to detect paclitaxel and IS at the
transitions m/z 854 / 286 and m/z 808.48 / 527.3, respectively. This method covered a
linearity range from 5 to 5000 ng/ml, with the total run time of 3.0 min. In summary, a high-
throughout UPLC-MS/MS method was successfully developed to measure paclitaxel in rat
plasma and was applied to pharmacokinetic study after intravenous administration of
paclitaxel.
ª 2013 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction cell lung, and prostate tumors [1e3]. Therefore, its commercialPaclitaxel (PTX) is a natural hydrophobic diterpenoid extrac-
tion from the bark of the Pacific yew. As mitotic inhibitor,
paclitaxel can stabilize and protect microtubules from disas-
sembly, and then interfere with the normal breakdown of
microtubules during cell proliferation. As an effective cancer
chemotherapy agent, it has been widely used for the treat-
ment of various tumors, including ovarian, breast, non-small320.
g Pharmaceutical Univer
sevier
ang Pharmaceutical Univformulation (Taxol, Bristol-Myers Squibb, New York, NY) has
been comprehensively used in clinic treatment [4e6]. For
example, it has been used for the first-line and second-line
treatment of ovarian cancer and nonsmall cell lung cancer
which is unsuitable for curative treatment. To achieve better
chemotherapy efficacy, it is necessary to timely monitor the
pharmaceutical pharmacokinetic parameters after intrave-
nous administration.sity
ersity. Production and hosting by Elsevier B.V. All rights reserved.
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plasma have already been reported. Earlier methods concen-
trated on the high performance liquid chromatography (HPLC)
with UV detector [7e9]. However, its application has been
severely limited due to its weakness of sensitivity and long
run time. Later, with the development of MS detector, liquid
chromatography-mass spectrometry (LC-MS) method [10,11]
and liquid chromatography-tandem mass spectrometry (LC-
MS/MS) are widely used for determination of paclitaxel in
biological samples. Vainchtein LD et al. [12] used an LC-MS/MS
method to determine plasma concentration of paclitaxel with
an LLOQ of 0.25 ng/ml, but the chromatographic separation
time was longer than 6 min and the plasma spiked volume
was 200 ml. With the introduction of ultra-performance liquid
chromatography (UPLC), the analysis efficiency has been
apparently improved. Zhang SQ et al. [13] reported by using
UPLC-MS/MS method, the chromatographic separation time
was achieved within 2 min with an LLOQ of 5 ng/ml, but this
method was only used for the determination of paclitaxel in
human plasma.
The aim of this research was to establish and validate a
rapid and sensitive method for quantitatively determination
the rat plasma concentration of paclitaxel using UPLC-MS/MS
technique. The validation results showed this method was
accurate, sensitive, high-throughout and suitable for appli-
cation in pharmacokinetic studies.Fig. 1 e Product ion scan spectra of paclitaxel (A) and
docetaxel (B).2. Materials and methods
2.1. Materials
Paclitaxel (PTX, 99.9% purity) and docetaxel (DTX, internal
standard, I.S., 99.9% purity) were obtained from Xi’an Helin
Biological Engineering Co. Ltd. (Xi’an, China). Commercial
Taxol solution was obtained from Shanghai Quanyu Pharm.
Co. (Shanhai, China). Acetonitrile and methanol of HPLC-
grade were purchased from Fisher Scientific (Pittsburgh, PA,
USA). Ultrapure water (>18 MU) was prepared by Easypure II
RF/UV system (Boston, MA, USA). Formic acid of HPLC-grade
was purchased from Dikma (Richmond Hill, NY, USA).
Diethyl ether of analytical grade was purchased from Concord
Tech. Co. (Tianjin, China) and high-purity nitrogen (99.999%)
was used. The plasma sample was collected at designated
time from the ocular region of the rats after centrifugation for
10 min. All the other reagents were of analytical grade.
2.2. UPLC-MS/MS conditions
Analyses were carried on an ACQUITY TQD system (Waters
Corp., Milford, MA, USA) equipped with cooling autosampler,
column oven and an ACQUITY triple-quadrupole tandem
mass spectrometric detection with an electrospray ionization
(ESI) interface (Waters Corp., Milford, MA, USA). An ACQUITY
UPLCTM BEH C18 column (50 mm  2.1 mm, 1.7 mm; Waters
Corp, Milford, MA, USA) was used. A gradient elutionwas used
to achieve chromatographic separation with a mobile phase
composed of mobile phase A (acetonitrile) andmobile phase B
(water, containing 0.1% formic acid). The mobile phase in the
gradient elution progress was: 0 min 50% B, 1.6 min 35% B,2.5min 50% B and 3min 50% B. The flow rate was set at 0.2ml/
min and the column temperature was maintained at 40 C.
The auto-sample temperature was set at 4 C and the injection
volume was 10 ml using the partial loop mode for sample in-
jection. The analytical run time for each sample was 3.0 min.
From 1.0 to 2.5 min, the elution was injected into the detector,
and the remainder was diverted to waste.
The separated compounds were detected by a Water Tan-
dem Quadrupole (TQ) Detector (Waters). Paclitaxel and I.S.
were monitored with the mass spectrometer by positive
electrospray ionization (ESI) interface mode. The ionization
source conditions were: source temperature 120 C, capillary
voltage 3.13 kV, cone voltage 35 V and desolvation tempera-
ture 380 C. The cone and desolvation gas flow rates were 50
and 550 l/h, respectively. The optimal collision energy was 20
and 10 V for paclitaxel and I.S., respectively. Argon was used
as collision gas at a pressure of approximately 0.0033 mbar.
Samples were analyzed by multiple reaction monitoring
(MRM) of the transitions of m/z 854 / 286 for PTX and m/z
808.48/ 527.3 for I.S., respectively. The scan time was set at
0.2 s per transition. Data were acquired by Masslynx 4.1
software.
2.3. Preparation of standards and quality control
samples
Stock solutions of paclitaxel and I.S. were prepared in aceto-
nitrile at a concentration of 100 mg/ml, respectively. To pre-
pare the working standard PTX solutions of desired
concentrations, the PTX stock solution was serially diluted
with mobile phase composed of solvent A (acetonitrile, 50%)
and solvent B (water, containing 0.1% formic acid, 50%). The
Fig. 2 e RepresentativeMRMchromatogramsofpaclitaxelanddocetaxel inratplasmasamples. (A)Blankplasmasample. (B)The
blankplasmasample spikedwithpaclitaxel at anLLOQof5ng/mLand IS. (C) Plasmasample froma rat, 10minafter intravenous
administration of Taxol solution. The retention time for paclitaxel and docetaxel was 1.94 and 1.89 min, respectively.
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Table 1 e Accuracy and precision for paclitaxel at the
plasma concentration of LLOQ (six replicates).
Analytes Added
concentration
(ng/mL)
Found
concentration
(ng/mL)
SD
(ng/mL)
RSD
(%)
RE
(%)
Paclitaxel 5 5.398 0.317 5.9 8.0
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final concentration of 1 mg/ml.
Calibration standards were prepared by spiking 50 ml drug-
free rat plasma with 50 ml of appropriate PTX standard solu-
tions. The effective concentrations in plasma samples were 5,
10, 50, 100, 200, 500, 1000, 2000 and 5000 ng/ml. The quality
control samples were prepared in a similar way to the cali-
bration standards at concentrations of 10, 200 and 4000 ng/ml.
2.4. Sample preparation
To a 50 ml of rat plasma, 50 ml of mobile phase and 50 ml of I.S.
solution (DTX, 1 mg/ml in the mobile phase) were added. Then
the sample mixture was vortexed for 1 min. To extract the
sample, 3 ml diethyl ether was added and then vortexed for
3 min, followed by centrifuged at 3500 rpm for 10 min. Then
the upper organic layer was taken out and evaporated to
dryness under a gentle nitrogen stream at 37 C. The residue
was reconstituted by 100 ml of mobile phase. After centrifuged
at 13,000 g for 10 min, a 10 ml aliquot of the supernatant was
then injected into the UPLC-MS/MS system for assay.
2.5. Method validation
The analytical method for quantitative determination of PTX
in rat sample was validated for selectivity, carryover, lower
limit of quantification (LLOQ), linearity, accuracy, precision,
matrix effect, extraction recovery, and stability. The different
validation parameters and the values for accepting the range
of validation parameters were in accordance with interna-
tional guidelines [14] and Food and Drug Administration
guidelines (www.fda.gov/cvm).
Selectivity was investigated by comparing chromatograms
of six different batches of blank plasma obtained from six rats
with those of corresponding standard blood samples spiked
with PTX and I.S. and a plasma sample obtained after intra-
venous administration.
Carryover was estimated by six continual injections of an
extracted blank sample after the injection of an extracted
upper limit of quantitation sample.
Quantitative determination of the plasma samples was
basedontheratioof thedetector responseofpaclitaxel to IS.The
standard curves in the form of y ¼ Aþ BX were calculated by
plotting the peak area ratio (Y ) against paclitaxel concentration
(X ) usingweighted (1/x2) least squares linear regression. During
routine analysis, each analytical run was consisted of a set of
calibration standards, a set of QC blood samples in duplicate at
intervals per batch and the blood samples to be analyzed.
Nine standard plasma samples ranging from 5 to 5000 ng/
ml were used to prepare the calibration standards. LLOQ was
defined as the lowest concentration of paclitaxel on the cali-
bration curve. The precision and accuracy were assessed by
analyzing six samples which were prepared in six replicates,
and the result should be less than 20%. Meanwhile, the signal/
noise ratio should be over 10.
The accuracy, intra- and inter-day precision were assessed
using QC samples at three concentration levels (10, 200 and
4000 ng/ml) on three separate days. The accuracy was defined
as the relative error (R.E.) and the precision was determined as
the relative standard deviation (RSD).To investigate the matrix effect (ME), six different lots of
blankplasmawere extractedand the spikedwith theanalyte at
different paclitaxel concentrations (10, 200 and 4000 ng/ml).
The corresponding peak areas (A) were then compared with
those of the paclitaxel standard solutions in mobile phase (B).
There was a matrix effect when the ratio (A/B  100) % was
<85% or >115%. The matrix effect of I.S. was evaluated in the
same procedure.
Extraction recovery of paclitaxel was defined as the ratio
between the mean peak area of the regularly extracted sam-
ples (10, 200 and 4000 ng/ml) and themean peak area of spike-
after-extraction plasma samples. The extraction recovery of IS
was evaluated in the same way using the medium level of QC
as a reference.
The stability of this method including sample post-
treatment (in the reconstituted extract at room temperature
for 4 h), sample storage (at room temperature for 24 h) and
freeze-thaw stability (three cycles) was investigated by
analyzing replicates (n ¼ 3) of QC samples (10, 200 and 4000 ng/
ml). The resultswere comparedwith those freshly preparedQC
samples and the percentage of concentration deviation was
calculated.
2.6. Pharmacokinetic study
The developed method was used to determine the plasma
concentration of paclitaxel in Taxol injection after intravenous
administration in six healthy adult female SD rats weighing
220  20 g (Laboratory Animal Center of Shenyang Pharma-
ceutical University, Shenyang, Liaoning, China). The rats were
deprived of food overnight but with free access to water before
experiments. All animals investigated in this research were
executed according to the Guidelines for the Care and Use of
Laboratory Animals approved by the Ethics Committee of An-
imal Experimentation of Shenyang Pharmaceutical University.
The Taxol solutionwas dilutedwith 0.9%NaCl to produce a
solution with PTX concentration of 1.5 mg/ml. The rats were
treated with diluted Taxol solution at dose of 8 mg/kg by
intravenous administration. Blood samples were collected
into heparinized tubes at 0.0833, 0.167, 0.25, 0.5, 1, 2, 4, 6, 8 and
10 h and centrifuged immediately at 13,000 g for 10 min. Then
the plasma was frozen at 80 C for analysis.3. Results and discussions
3.1. Method development
Paclitaxel has a higher sensitivity achieved by ESI source
rather than APCI and a stronger response in the positive-ion
Table 2 e Precision and accuracy of the UPLC-MS/MS
method to determine paclitaxel in rats plasma (n[ 3
days, six replicates per day).
Added
conc. (ng/mL)
Found
conc. (ng/mL)
R.S.D. (%) R.E. (%)
Day 1 10 9.80 9.64 2.00
200 176.47 1.38 11.77
4000 3579.89 3.87 10.50
Day 2 10 10.60 3.88 5.98
200 175.34 1.68 12.33
4000 3607.87 3.24 9.80
Day 3 10 9.99 8.14 0.07
200 176.79 1.36 11.60
4000 3746.77 2.04 6.33
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was used for the detection of paclitaxel and IS. Through pos-
itive ion full-scan spectra, the predominant protonated mo-
lecular ion [M þ H]þ for the analytes were 854 and 808.48,
respectively. In order to capture the strongest ion intensity,
parameters such as ESI source temperature, capillary and
cone voltage were optimized. Then in the collision induced
dissociation condition, the abundant product irons were ob-
tained at m/z of 286 and 527.3 for paclitaxel and IS, respec-
tively. The product-ion spectra of these compounds are
shown in Fig. 1.
In the chromatographic optimizing process, Acetonitrile
was used in the mobile phase instead of methanol because of
its lower background noise. Adding formic acid could obvi-
ously improve detection sensitivity presumably induced by
facilitative ionization of the analytes. Therefore, the mobile
phase was consisted of water (0.1% formic acid)-acetonitrile.
As described in Section 2.2, a gradient elution progress was
used to completely separate paclitaxel and IS. The total run
time for both the analyteswas 3.0min. From 1.0 to 2.5min, the
elution was injected into the detector, and the remainder was
diverted to waste for avoidance the contamination of ion
source by impurities.
Protein precipitation and liquideliquid extraction
methods were compared during the sample preparation. The
former method was discarded because of high noise and the
poor LLOQ of only 25 ng/ml. In the liquideliquid extraction
method, diethyl ether was used as the extraction solvent, the
higher extraction and lower background noise were also
obtained. Nevertheless, the extraction recovery was onlyTable 3 e Stability of paclitaxel in rat plasma (three replicates)
Storage conditions Added conc. (ng/mL)
24 h at room temperature 10
200
4000
4 h at room temperature
after extraction
10
200
4000
After three freeze/thaw cycles 10
200
4000about 70% when the samples were extracted by 2 ml diethyl
ether, so we added 3 ml diethyl ether to improve the
extraction recovery. The following steps were conducted as
Section 2.4.
3.2. Method validation
3.2.1. Selectivity
As shown in Fig. 2, it was obviously that there was no inter-
ference from endogenous substances in blood at the retention
time of the analytes.
3.2.2. Carryover
Carryover study indicated that the carryover from residues in
sampling/switching valves and late-eluting residues in the
column was both negligible.
3.2.3. Linearity and LLOQ
The linear regression was obtained between the peak area
ratios and the paclitaxel concentration ranging from 5 to
5000 ng/ml in rat plasma. A typical calibration curve equation
was:y ¼ 2:18903  xþ 15:2838ðr ¼ 0:9960Þ, where y is the peak
area ratio of PTX to IS, and x is the concentration of PTX. This
concentration range showed a good linearity (r > 0.99) in all
analytical runs. The calibration curve for each run was
exhibited in Table 4.
LLOQ was established by this method at concentration of
5 ng/ml for paclitaxel, which was suitable for quantitative
determine the plasma concentration of Taxol injection after
intravenous administration. The accuracy and precision
values of LLOQ were exhibited in Table 1.
3.2.4. Precision and accuracy
Table 2 summarized the accuracy and precision for paclitaxel
from QC samples. The data was listed for each day individu-
ally. The results showed a good precision that all the values
were below 9.64%. The accuracy ranged from 12.33% to
5.98%,whichwas also acceptable. The results above illustrated
that this UPLC-MS/MS method was precise and accurate.
3.2.5. Matrix effect
All the matrix effect ratios (A/B  100) % for PTX and I.S. were
between 91.73% and 103.39%, which were within the accept-
able limits (90.0%e110.0%). This result means that there was
no ion suppression and enhancement phenomenon from
plasma matrix..
Found conc. (ng/mL) R.S.D. (%) R.E. (%)
9.85 5.34 1.53
190.02 0.97 4.99
4140.42 1.78 3.51
10.47 2.69 4.70
193.51 3.09 3.24
3854.14 2.20 3.65
10.25 2.64 2.50
190.44 2.90 4.78
4069.64 1.99 1.74
Table 4 e The calibration curve of paclitaxel for each run.
Run Calibration curve r
1 y ¼ 2:18903  xþ 15:2838 0.9960
2 y ¼ 1:5711  xþ 11:2554 0.9923
3 y ¼ 2:43747  xþ 26:2739 0.9969
4 y ¼ 1:64999  xþ 32:4629 0.9936
5 y ¼ 1:13436  xþ 7:98519 0.9975
6 y ¼ 2:21728  xþ 14:958 0.9917
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Mean extraction recoveries of PTX at 10, 200, 4000 ng/ml were
90.15  3.51%, 98.47  7.77% and 88.30  2.23%, respectively.
The extraction recovery of I.S. was 90.31  4.67%.
The relative errors of all the QC samples in the
stability experiment were below 5.5%, which could be seen
in Table 3, indicating that there was no significant
degradation of PTX under the condition described previously.3.3. Application
This developed method was successfully used to determine
the plasma concentration of paclitaxel after intravenous
administration of Taxol injection (8 mg/kg). At designated
times, blood sample were collected up to 10 h after intrave-
nous administration. Our preliminary work indicated that the
high PTX blood concentrations of the first 30 min samples
were out of the calibration range, so these samples were
detected after 10 fold dilution. The feasibility of this method
was also validated in our previous work (Data not shown).
The mean plasma concentrationetime curve of paclitaxel
is shown in Fig. 3. The results showed that after single dose of
8 mg/kg Taxol solution, the mean half-life (T1/2) and the
mean residence time (MRT) were calculated to be
5.85  3.42 h and 2.91  1.07, respectively. The mean area
under the plasma concentration versus time curve (AUC0-N)
was 15.05  3.12 mg h/ml.
Regarding the relatively easy sample preparation method
(liquideliquid extraction) and short chromatographic run0
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Fig. 3 e Mean plasma concentrationetime curve of
paclitaxel after a single intravenous dose of 8 mg/kg to six
rats (mean ± SD).time (within 3 min), about 200 samples could be analyzed
routinely per day. This convenient and rapidmethod is able to
meet the requirements of pharmacokinetic study for
paclitaxel.4. Conclusion
We have developed and validated a rapid and sensitive UPLC-
MS/MS method for quantitatively high-throughput determi-
nation of paclitaxel. Through a rapid liquideliquid extraction
process, this method was suitable for application in pharma-
cokinetic studies of paclitaxel in rats after intravenous
administration.
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